INBRX-105 is under clinical development by Inhibrx and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how INBRX-105’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INBRX-105 (ES-101) is under development for the treatment of solid tumors, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, urothelial cell carcinoma, small cell lung cancer, esophageal squamous cell carcinoma (ESCC) and non-small cell lung cancer. It is administered through the intravenous route. The drug candidate is a tetravalent single domain antibody (sdAb)-based bi-specific monoclonal antibody that acts by targeting tumor necrosis factor receptor superfamily member 9 (4-1BB or CD137) and cells expressing programmed cell death 1 ligand 1 (PD-L1).
It was also under development for the treatment of Hodgkin and Non-Hodgkin lymphoma.
Inhibrx is a biotechnology company that discovers and develops biologic therapeutics for the treatment of cancer and infectious diseases. It is investigating INBRX-101, a recombinant human AAT-Fc fusion protein candidate for the treatment of AATD (alpha-1 antitrypsin deficiency); INBRX-109, an engineered tetravalent sdAb-based therapeutic candidate to treat cancer by activating DR5 (death receptor 5). The company is also evaluating INBRX-106 program against advanced or metastatic solid tumors; and INBRX-105 therapeutic candidate targeting patients with programmed death-ligand 1 (PD-L1) expressing tumors. It utilizes its proprietary sdAb (single-domain antibody) platform to develop biotherapeutics that interface with the biology of each target antigen by focusing on immune activation and mediating enhanced signaling. Inhibrx is headquartered in La Jolla, California, the US.
For a complete picture of INBRX-105’s drug-specific PTSR and LoA scores, buy the report here.